Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. - Kollmannsberger,C.; Hartmann,J.T.; Kanz,L.; Bokemeyer,C. (J Cancer Res Clin Oncol, 1998)